---
document_datetime: 2023-09-21 20:28:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_en.pdf
document_name: vitrakvi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9540043
conversion_datetime: 2025-12-20 16:43:59.266739
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/19/1385/001 | VITRAKVI          | 25 mg      | Capsule, hard         | Oral use                  | bottle (HDPE)         |                           | 56 capsules |
| EU/1/19/1385/002 | VITRAKVI          | 100 mg     | Capsule, hard         | Oral use                  | bottle (HDPE)         |                           | 56 capsules |
| EU/1/19/1385/003 | VITRAKVI          | 20 mg/ml   | Oral solution         | Oral use                  | bottle (glass)        | 100 ml                    | 1 bottle    |
| EU/1/19/1385/004 | VITRAKVI          | 20 mg/ml   | Oral solution         | Oral use                  | bottle (glass)        | 50 ml                     | 2 bottles   |